UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 29, 2004
--------------------------
PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada 0-9410 90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 865/769-4011
--------------------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On June 29, 2004, Provectus Pharmaceuticals, Inc. (the "Company") announced
that it completed a fixed price financing of $1 million for the purchase of
restricted common shares.
The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press release dated June 29, 2004.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Provectus Pharmaceuticals, Inc.
Dated: June 29, 2004 By:/s/ H. Craig Dees
------------------------------------------
H. Craig Dees
Chief Executive Officer
Exhibit Index
Exhibit No. Description
-------------- -----------
99.1 Press Release of Provectus Pharmaceuticals, Inc.
X-1